Atripla, the first once-daily HIV pill (2006)
The FDA approved Atripla, the first single-tablet HIV regimen, combining efavirenz, emtricitabine, and tenofovir. It collapsed what had been multi-pill 'cocktail' therapy into one daily tablet.
Within a few years, once-daily single tablets became the default for most newly treated patients.
The single-tablet era shifted HIV care from pill burden toward simplicity, setting the template Bixlenvo follows.
Bixlenvo is the latest chapter in the same consolidation: shrinking complex regimens into one pill, this time for patients with drug resistance.
